QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-cytokinetics-raises-price-target-to-82

Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $71 to $82.

 b-of-a-securities-maintains-neutral-on-cytokinetics-raises-price-target-to-56

B of A Securities analyst Jason Zemansky maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and raises the price target fro...

 hc-wainwright--co-reiterates-buy-on-cytokinetics-maintains-120-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ: CYTK) with a Buy and maintains $120 price ...

 cytokinetics-presents-additional-data-related-to-aficamten-in-late-breaking-clinical-research-session-at-hfsa-annual-scientific-meeting-2025

Additional Data from MAPLE-HCM Show Aficamten Significantly Improves Measures of Maximaland Submaximal Exercise Capacity and Re...

 b-riley-securities-maintains-buy-on-cytokinetics-raises-price-target-to-80

B. Riley Securities analyst Mayank Mamtani maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from ...

 hc-wainwright--co-reiterates-buy-on-cytokinetics-maintains-120-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $120 price t...

 on-sept-15-cytokinetics-participates-in-fda-late-cycle-meeting-for-nda-for-aficamten-pdufa-target-action-date-for-aficamten-nda-is-dec-26-2025--continues-to-expect-differentiated-label--risk-mitigation-profile-for-aficamten-if-approved-by-fda

-SEC Filing

 cytokinetics-announces-550m-private-offering-of-convertible-notes-due-2031

Cytokinetics, Incorporated ("Cytokinetics") (NASDAQ:CYTK) today announced its intention to offer, subject to market con...

 barclays-maintains-overweight-on-cytokinetics-raises-price-target-to-71

Barclays analyst Gena Wang maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $53 to $71.

 evercore-isi-group-maintains-outperform-on-cytokinetics-raises-price-target-to-80

Evercore ISI Group analyst Cory Kasimov maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target f...

 stifel-maintains-buy-on-cytokinetics-raises-price-target-to-96

Stifel analyst James Condulis maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $87 to $96.

 cytokinetics-cytk-stock-is-skyrocketing-tuesday-whats-driving-the-action

Shares of Cytokinetics are trading sharply higher Tuesday. The company presented new long-term safety and efficacy data for its...

 jmp-securities-reiterates-market-outperform-on-cytokinetics-maintains-78-price-target

JMP Securities analyst Jason N. Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $78 pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION